Anti-factor xa test

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch


Heparin Anti-Xa activity; Heparin monitoring

This section has been translated automatically.

Diagnostic method for control/monitoring of therapy with unfractionated heparin (UF) and low molecular weight heparin (LMW), especially in

  • serious damage to the liver or kidneys
  • high body weight (> 150 kg)
  • low body weight (< 40 kg)
  • during pregnancy
  • for children and newborns

General information
This section has been translated automatically.

Sample material: 1 ml citrate plasma

Removal instructions: The blood sample should be taken 2 - 4 h after the last administration of heparin. For longer transport, centrifuge citrate blood after collection, pipette the plasma into a separate tube (without additives) and freeze (approx. - 20°C)

Sample transport Postal shipment possible: Sample transport cooled (+ 2°C - + 8°C) or deep-frozen (approx. - 20°C)

This section has been translated automatically.

Reference value: For adults the reference value is: 0,4 - 1 IU/ml. This range corresponds to the therapeutic range and is to be adapted individually. The prophylactic range is 0.2 - 0.4 IU/ml for orientation and must be adapted individually.

This section has been translated automatically.

  1. Chaaya G et al (2016) Rivaroxaban-induced leukocytoclastic vasculitis: A challenging rash. Ann Allergy Asthma Immunol 116:577-578.
  2. Gressenberger P (2019) Bleeding complications under DOAKs and their handling Z VESSELS 16: 5-8
  3. Chohan SA et al (2020) Bullous pemphigoid-like skin rash associated with rivaroxaban use in a very elderly patient with multimorbidity and chronic kidney disease: A case report. Clin Case Rep 8:725-730.
  4. Ferreira C et al (2018) Bullous pemphigoid-like skin eruption during Treatment with Rivaroxaban: A Clinical Case Study. Eur J Case Rep Internal Med 5:000724.
  5. Heidbuechel A et al (2013) European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15: 625-651.
  6. Murer LM et al (2016) Rivaroxaban Therapy, False-Positive Lupus Anticoagulant Screening Results, and Confirmatory Assay Results. Lab Med 47:275-278.
  7. Masahir I et al (2016) Profiles of direct oral anticoagulants and clinical usage -dosage and dose regimen differences. J Intensive Care 4: 19.
  8. Naito T et al (2018) Pulmonary embolism and deep vein thrombosis in eosinophilic granulomatosis with polyangiitis successfully treated with rivaroxaban. Respir Med Case Rep25:33-35.
  9. Pop MK et al (2018) Drug-induced thrombocytopenia after anticoagulation with rivaroxaban. On J Emerg Med 36: 531.e1-531.e2.
  10. Ruff CT et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials. Lancet 383: 955-62.
  11. Sherwood MW et al (2015) Gastrointestinal bleeding in patients with atrial fibrillation treated with Rivaroxaban or Warfarin: ROCKET AF Trial. J Am Coll Cardiol 66: 2271-2281.
  12. Schwarb H et al (2016) New direct oral anticoagulants (DOAC) and their use today. Dent J (Basel) 4: 5.
  13. Vu TT et al (2017) Adverse Drug Reactions and Cutaneous Manifestations Associated With Anticoagulation. J Cutan Med Surg 21:540-550.
  14. Weishaupt C ET al (2016) Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol 3:e72-e79.
  15. Willet CK et al (2017) Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence. Ther Clin Risk Manag 13: 447-454.

Incoming links (1)



Last updated on: 29.10.2020